On 27 September 2018, the FDA approved dacomitinib (Vizimpro, Pfizer) as a first-line therapy for patients with metastatic NSCLC or EGFR with Del19 or exon 21 L858R mutations, as detected by an FDA-approved test (Reckamp et al., 2014; Wu et al., 2017a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.